Most Cancer Trial Centers Located Closer to White, Affluent PopulationsMarch 21, 2024Patient & Survivor CareDLBCLMixed TopicsPediatricsAggressive LymphomasALLAML
Are Food Emulsifiers Associated With Increased Cancer Risk?February 23, 2024Patient & Survivor CareDLBCLAggressive LymphomasALLAMLB Cell LymphomaCLL
Democratic Lawmakers Press Pfizer on Chemotherapy Drug ShortagesFebruary 22, 2024DLBCLMixed TopicsPatient & Survivor CareAggressive LymphomasALLAMLBleeding Disorders
Hematology is in the Brodsky family’s bloodDecember 6, 2023Mixed TopicsCMLBleeding DisordersTransplantThrombosisAnemiaMyelodysplastic Syndrome
ASH 2023: Equity, Sickle Cell, and Real-Life OutcomesDecember 4, 2023Mixed TopicsBleeding DisordersAMLThrombosisTransplantMultiple MyelomaMyelodysplastic Syndrome
FDA OKs new agent to block chemotherapy-induced neutropeniaNovember 29, 2023Mixed TopicsAggressive LymphomasB Cell LymphomaDLBCLHodgkin LymphomaIndolent LymphomaMantle Cell Lymphoma
Study confirms small blood cancer risk from CT scansNovember 15, 2023ALLCLLAMLMyelodysplastic SyndromeCMLPediatrics
FDA OKs ivosidenib for IDH1-mutated myelodysplastic syndromesOctober 25, 2023Myelodysplastic Syndrome
Using JAK inhibitors for myelofibrosisSeptember 11, 2023Myelodysplastic SyndromeAMLAnemiaBleeding DisordersMixed TopicsThrombosisTransfusion Medicine
CHP/CCUS: Low blood cancer risk for most patientsSeptember 8, 2023Mixed TopicsMyelodysplastic SyndromeAnemiaThrombosisPatient & Survivor CareBleeding Disorders
ESMO helps hematologists assess new cancer drugsJune 28, 2023Mixed TopicsCellular TherapyCMLCLLAggressive LymphomasALLAML
Multiprong strategy makes clinical trials less WhiteJune 23, 2023Diversity in MedicinePatient & Survivor CareDLBCLALLAggressive LymphomasAMLB Cell Lymphoma
CBSM phone app eases anxiety, depression in cancer patientsJune 23, 2023Patient & Survivor CareDLBCLAggressive LymphomasALLAMLCLLCML
Drugmakers are abandoning cheap generics, and now U.S. cancer patients can’t get medsJune 22, 2023Patient & Survivor CareDLBCLAggressive LymphomasALLAMLAnemiaB Cell Lymphoma
CMML: GM-CSF inhibitor lenzilumab shows early promiseJune 20, 2023CMLAMLMyelodysplastic SyndromeMixed Topics
